

CURRICULUM VITAE DI NICOLA BATTELLI
aggiornato al 11/04/2022

INFORMAZIONI PERSONALI

Cognome / Nome	BATTELLI NICOLA
Anno di nascita	1969
Qualifica	Medico Oncologo
Amministrazione	ASUR Marche A.V.3
Struttura di appartenenza	Ospedale Generale Provinciale di Macerata, ASUR Marche area vasta n°3
Incarico attuale e servizio di afferenza	Direttore U.O.C. Oncologia
Num. Tel. Ufficio	0733 2572881
Fax dell'Ufficio	0733 2572526
E-mail istituzionale	nicola.battelli@sanita.marche.it

TITOLI DI STUDIO E PROFESSIONALI, ESPERIENZE LAVORATIVE, ALTRE CONOSCENZE

Titolo di studio	Laurea in Medicina e Chirurgia					
Altri titoli di studio e professionali	Specializzazione in Oncologia					
Esperienze professionali (incarichi ricoperti)	<ul style="list-style-type: none"> • <i>Da Settembre 2017: Direttore U.O.C. Oncologia, Ospedale di Macerata, Area vasta N°3</i> • <i>Gennaio 2017- Agosto 2017: Direttore U.O.C. Oncologia, Ospedale di Jesi, Area vasta N°2</i> • <i>Luglio 2000 - Dicembre 2016: Medico Oncologo, Ospedale di Ancona, Area vasta n°2</i> • <i>Marzo 1999 – Ottobre 2000: Dirigente Medico I Livello, Oncologia Medica di Ancona</i> 					
Capacità linguistiche <i>(stima della conoscenza linguistica sulla base del Quadro Comune Europeo di Riferimento delle Lingue)</i>	Comprensione		Parlato		Produzione scritta	
	Lingua conosciuta	Ascolto	Letture	Interazione	Produzione orale	
	Inglese	B2	B2	B1	B1	B1
Legenda livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato						

<p>Capacità nell'uso delle tecnologie</p>	<p>Conoscenza ed uso dei seguenti programmi: Windows XP e precedenti, Pacchetto Office, Power Point, File Maker Pro, Regolo, SAS 8.2, MedCalc, DOSSIER.</p>
<p>Partecipazione a convegni, seminari, workshop ecc.</p>	<p>Ha partecipato a numerosi congressi nazionali e internazionali in qualità di discussant, relatore e moderatore. Ha partecipato a numerosi corsi (principalmente sulle neoplasie mammarie) invitato come esperto in ambito nazionale. E' autore di diverse pubblicazioni scientifiche molte delle quali pubblicate in riviste internazionali indicizzate.</p>
<p>Attività di docenza</p>	<p>Negli anni 2003, 2005, 2006, 2007, e dal 2011 al 2015 è stato docente della Scuola di Specialità in Oncologia Medica dell'Università di Ancona.</p>
<p>Ricerca clinica</p>	<p>Esperienza come <i>Principal Investigator</i> in diversi studi di fase II, III, IV e osservazionali, in accordo alle GCP. Ultimo training GCP per ICH E6 (R2) GCP effettuato il 22/10/ 2020.</p>
<p>Pubblicazioni</p>	<ol style="list-style-type: none"> 1. Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clin Genitourin Cancer. 2022 Feb 19:S1558-7673(22)00039-8. 2. Rebuzzi SE, Cerbone L, Signori A, Santoni M, Murianni V, De Giorgi U, Procopio G, Porta C, Milella M, Basso U, Massari F, Maruzzo M, Iacovelli R, Battelli N, Carnisciano L, Banna GL, Buti S, Fornarini G. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Ther Adv Med Oncol. 2022 Feb 26;14:17588359221079580 3. Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. Eur Urol Focus. 2022 Feb 19:S2405-4569(22)00049-9. 4. Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol. 2022 Feb;170:103596. 5. Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021 Dec;17(12):1455-1466. 6. Aurilio G, Santoni M, Massari F, Cimadamore A, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers (Basel). 2021 Oct 18;13(20):5229. doi: 10.3390/cancers13205229. 7. Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2021 Dec;22(17):2323-2336. 8. Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. 9. Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):45-51.

10. Santoni M, Massari F, Montironi R, **Battelli N**. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. *Biochim Biophys Acta Rev Cancer*. 2021 Aug;1876(1):188547.
11. Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, **Battelli N**, Santoni M, Massari F. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. *Pathol Res Pract*. 2021 Jun;222:153440.
12. Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, **Battelli N**, Montironi R. Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. *Transl Androl Urol*. 2021 Mar;10(3):1562-1568.
13. Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, **Battelli N**. An update on investigational therapies that target STAT3 for the treatment of cancer. *Expert Opin Investig Drugs*. 2021 Mar;30(3):245-251.
14. Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, **Battelli N**, Montironi R, Massari F. Treating Prostate Cancer by Antibody-Drug Conjugates. *Int J Mol Sci*. 2021 Feb 4;22(4):1551.
15. Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Carteni G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, **Battelli N**. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? *Diagnostics (Basel)*. 2021 Jan 18;11(1):138.
16. Santoni M, Piva F, Cimadamore A, Giulietti M, **Battelli N**, Montironi R, Cosmai L, Porta C. Exploring the Spectrum of Kidney Ciliopathies. *Diagnostics (Basel)*. 2020 Dec 16;10(12):1099.
17. Piva F, Tartari F, Giulietti M, Aiello MM, Cheng L, Lopez-Beltran A, Mazzucchelli R, Cimadamore A, Cerqueti R, **Battelli N**, Montironi R, Santoni M. Predicting future cancer burden in the United States by artificial neural networks. *Future Oncol*. 2021 Jan;17(2):159-168.
18. Santoni M, Miccini F, **Battelli N**. Gut microbiota, immunity and pain. *Immunol Lett*. 2021 Jan;229:44-47.
19. Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, Baldessari C, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Maruzzo M, Rossi E, Grossi F, Casadei C, Cortellini A, Verderame F, Montesarchio V, Rizzo M, Mencoboni M, Zustovich F, Fratino L, Cinieri S, Negrini G, Banzi M, Sorarù M, Zucali PA, Lacidogna G, Russo A, **Battelli N**, Fornarini G, Mucciarini C, Bracarda S, Bonetti A, Pezzuolo D, Longo L, Sartori D, Iannopollo M, Cavanna L, Meriggi F, Tassinari D, Corbo C, Gemone A, Prati V, Carnio S, Giordano P, Dicorato AM, Verusio C, Atzori F, Carozza F, Gori S, Castro A, Pilotto S, Vaccaro V, Garzoli E, Di Costanzo F, Maiello E, Labianca R, Pinto C, Tognetto M, Buti S. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. *Ther Adv Med Oncol*. 2020 Nov 2;12:1758835920968463.
20. Marinelli O, Romagnoli E, Maggi F, Nabissi M, Amantini C, Morelli MB, Santoni M, **Battelli N**, Santoni G. Exploring treatment with Ribociclib alone or in sequence/combo with Everolimus in ER⁺HER2-Rb wild-type and knock-down in breast cancer cell lines. *BMC Cancer*. 2020 Nov 19;20(1):1119.
21. Santoni M, Massari F, Aurilio G, Mollica V, Cimadamore A, Lopez-Beltran A, Cheng L, **Battelli N**, Nolè F, Montironi R. Designing novel immunocombinations in metastatic renal cell carcinoma. *Immunotherapy*. 2020 Dec;12(17):1257-1268.
22. Aiello MM, Solinas C, Santoni M, **Battelli N**, Restuccia N, Latteri F, Paratore S, Verderame F, Albanese GV, Bruzzi P, Soto Parra HJ. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. *Front Oncol*. 2020 Sep 2;10:1167.
23. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo

- A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, **Battelli N**, Fagnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. *Eur J Cancer*. 2020 Jul;134:19-28.
24. Occhipinti G, Romagnoli E, Santoni M, Cimadamore A, Sorgentoni G, Cecati M, Giulietti M, **Battelli N**, Maccioni A, Storti N, Cheng L, Principato G, Montironi R, Piva F. Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. *Front Genet*. 2020 Apr 15;11:349.
25. Mollica V, Santoni M, Di Nunno V, Cimadamore A, Cheng L, Lopez-Beltran A, **Battelli N**, Montironi R, Massari F. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. *Curr Drug Targets*. 2020;21(14):1463-1475.
26. Di Nunno V, Santoni M, Mollica V, Conti A, Montironi R, **Battelli N**, Ardizzoni A, Massari F. Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. *Clin Drug Investig*. 2020 Mar;40(3):211-226
27. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Carteni G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, **Battelli N**. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. *Cancers (Basel)*. 2019 Dec 30;12(1):84.
28. Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, **Battelli N**, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. *Expert Rev Cardiovasc Ther*. 2019 Dec;17(12):917-927.
29. Aurilio G, Piva F, Santoni M, Cimadamore A, Sorgentoni G, Lopez-Beltran A, Cheng L, **Battelli N**, Nolè F, Montironi R. The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. *Int J Mol Sci*. 2019 Nov 13;20(22):5683.
30. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, **Battelli N**, Montironi R, Massari F. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. *Expert Rev Mol Diagn*. 2020 Feb;20(2):207-217.
31. Santoni M, Heng DY, Aurilio G, Iozzelli A, Servi L, Fabiani A, Giannini M, Mazzucchelli R, Cimadamore A, Scarpelli M, Zaghoul MS, **Battelli N**, Montironi R. Combining radiotherapy with immunotherapy or CAR-T in Renal Cell Carcinoma. *Curr Drug Targets*. 2019 Oct 17.
32. Santoni M, Aurilio G, Maccioni A, Nolè F, **Battelli N**. Key players of neuroendocrine differentiation in prostate cancer. *Ann Transl Med*. 2019 Jul;7(Suppl 3):S112.
33. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, Principato G, Saladino T, Piva F, **Battelli N**. Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. *BioDrugs*. 2019 Sep 16.
34. Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, **Battelli N**, Brandi G, Massari F. BAP1 in solid tumors. *Future Oncol*. 2019 Jun;15(18):2151-2162.
35. Santoni M, Maiorani G, Faloppi L, Di Nunno V, Gatto L, Massari F, **Battelli N**. Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. *Ann Transl Med*. 2019 Mar;7(Suppl 1):S39.
36. Di Nunno V, Mollica V, Gatto L, Santoni M, Sorgentoni G, **Battelli N**, Massari F. Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? *Ann Transl Med*. 2019 Mar;7(Suppl 1):S38.

37. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, **Battelli N**, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. *Front Oncol.* 2019 Apr 5;9:228.
38. Santoni M, Conti A, Buti S, Bersanelli M, Foghini L, Piva F, Giulietti M, Lusuardi L, **Battelli N**. Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. *Immunotherapy.* 2018 Nov;10(15):1303-1313.
39. Carrozza F, Santoni M, Piva F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, **Battelli N**, Tamberi S. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. *Crit Rev Oncol Hematol.* 2018 Nov;131:1-6.
40. Santoni G, Morelli MB, Amantini C, **Battelli N**. Urinary Markers in Bladder Cancer: An Update. *Front Oncol.* 2018 Sep 7;8:362.
41. Santoni M, Montironi R, **Battelli N**. Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. *N Engl J Med.* 2018 Jul 5;379(1):91-2.
42. Giulietti M, Santoni M, Cimadamore A, Carrozza F, Piva F, Cheng L, Lopez-Beltran A, Scarpelli M, **Battelli N**, Montironi R. Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. *Front Oncol.* 2018 Jun 13;8:221.
43. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, **Battelli N**, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. *Expert Rev Mol Diagn.* 2018 Jul;18(7):645-655.
44. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, **Battelli N**, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. *Drugs Context.* 2018 Jun 5;7:212528.
45. Massari F, Santoni M, di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, **Battelli N**, Montironi R. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. *Cancer Treat Rev.* 2018 Jul;68:80-85.
46. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, **Battelli N**. Tivozanib for the treatment of renal cell carcinoma. *Expert Opin Pharmacother.* 2018 Jun;19(9):1021-1025.
47. Santoni M, **Battelli N**, Buti S. Durvalumab in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med.* 2018 Mar 1;378(9):869. doi: 10.1056/NEJMc1716426.
48. Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, **Battelli N**, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. *Cancer Treat Rev.* 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Review.
49. Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M, Giannini M, Cognigni PD, Ferrara G, **Battelli N**. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. *Biochim Biophys Acta.* 2018 Jan;1869(1):78-84. doi: 10.1016/j.bbcan.2017.10.007. Epub 2017 Nov 7. Review.
50. Ballatore Z, Pistelli M, **Battelli N**, Pagliacci A, De Lisa M, Berardi R, Cascinu S. Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. *BMC Res Notes.* 2016 Nov 28;9(1):497.
51. Pistelli M, Ballatore Z, Santinelli A, Biscotti T, Piva F, Occhipinti G, Della Mora A, Pagliacci A, **Battelli N**, Bastianelli L, De Lisa M, Bracci R, Maccaroni E, Berardi R, Cascinu S. Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. *Oncol Rep.* 2016 Aug;36(2):755-62. doi: 10.3892/or.2016.4903. Epub 2016 Jun 22.
52. Guerra F, Marchesini M, Contadini D, Menditto A, Morelli M, Piccolo E, **Battelli N**, Pistelli M, Berardi R, Cascinu S, Capucci A. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. *Support Care Cancer.* 2016 Jul;24(7):3139-45. doi: 10.1007/s00520-016-3137-y. Epub 2016 Feb 29.
53. Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, **Battelli N**, Ridolfi F, Santoni M, Maccaroni E, Bracci R, Santinelli A, Biscotti T, Berardi R, Cascinu S. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. *BMC Cancer.* 2015 Mar 28;15:195. doi:

10.1186/s12885-015-1204-2.

54. Sanna G, Fabi A, Crivellari D, Saracchini S, **Battelli N**, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L. Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial. *Tumori*. 2014 Jul-Aug;100(4):432-8. doi: 10.1700/1636.17904.
55. Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M, Ballatore Z, Ridolfi F, Maccaroni E, Bracci R, Berardi R, **Battelli N**, Cascinu S. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. *Cancers (Basel)*. 2014 Jun 27;6(3):1351-62. doi: 10.3390/cancers6031351.
56. Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P. Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.; "FOLLOW-UP" Study Group. *PLoS One*. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.
57. Pistelli M, Pagliacci A, **Battelli N**, Santinelli A, Biscotti T, Ballatore Z, Berardi R, Cascinu S. Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. *Anticancer Res*. 2013 Jun;33(6):2737-42.
58. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, **Battelli N**, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. *Breast Cancer Res Treat*. 2012 Jul;134(1):283-9. doi: 10.1007/s10549-012-2045-1. Epub 2012 Apr 4.
59. **Battelli N**, Bittoni A, Pagliacci A, Zeponi L, Scartozzi M, Mariotti C, Cascinu S. Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. *Tumori*. 2011 Jul-Aug;97(4):449-53. doi: 10.1700/950.10396.
60. Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandarà M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancellato G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, **Battelli N**, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G; OMERO Group. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. *Ann Oncol*. 2008 Oct;19(10):1706-12. doi: 10.1093/annonc/mdn369. Epub 2008 Jun 9.
61. Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreatta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, **Battelli N**, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. *Breast Cancer Res Treat*. 2008 Jul;110(1):127-34. Epub 2007 Aug 9.
62. Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulas V, **Battelli N**, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G, Petruzella L; Navelbine Herceptin Project. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. *Br J Cancer*. 2006 Oct 9;95(7):788-93. Epub 2006 Sep 12.
63. **Battelli N**, Massacesi C, Braconi C, Pilone A, Manzione L, Dinota A, Cobelli S, Scanni A, Sturba F, Giacomini G, Morale D, Giorgi F, Tummarello D, Cascinu S. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. *Am J Clin Oncol*. 2006 Aug;29(4):380-4.
64. Berardi R, Grilli G, Romagnoli E, Saladino T, Freddari F, Tamburrano T, Galizia E, Carbonari G, Mariani C, Braconi C, Pierantoni C, **Battelli N**, Scartozzi M, Cascinu S. Paraneoplastic syndromes: a review]. *Clin Ter*. 2005 Nov-Dec;156(6):281-8. Review. Italian.
65. Massacesi C, Marcucci F, Boccetti T, **Battelli N**, Pilone A, Rocchi MB, Bonsignori M. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. *J Exp Clin Cancer Res*. 2005 Mar;24(1):43-8.
66. Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni

S, Zaniboni A, **Battelli N**, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol. 2002 May;13(5):716-20.

67. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, **Battelli N**, Cascinu S. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol. 2000 Oct;11(10):1263-6.

68. Lippe P, Silva RR, Giuliodori L, Cancellieri MA, **Battelli N**, Massacesi C, Berardi R, Bissoni R, Gesuita R, Cellerino R. Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study. Minerva Med. 2000 Mar-Apr;91(3-4):53-7.

69. Cascinu S, Frontini L, Comella G, Barni S, Labianca R, **Battelli N**, Casaretti R, Zonato S, Pirovano M, Catalano G, Cellerino R. Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 1999 Feb;79(3-4):491-4.

70. Tummarello D, Lippe P, Bracci R, Mari D, Monterubbiansi MC, **Battelli N**. First line chemotherapy in patients with brain metastases from non-small and small cell lung cancer. Oncol Rep. 1998 Jul-Aug;5(4):897-900.

71. Cascinu S, Catalano V, Baldelli AM, Scartozzi M, **Battelli N**, Graziano F, Cellerino R. Locoregional treatments of unresectable liver metastases from colorectal cancer. Cancer Treat Rev. 1998 Feb;24(1):3-14. Review.

72. Cascinu S, **Battelli N**, Graziano F, Ghi M, Silva R, Nacciarriti D, Cellerino R. c-erbB-2 and common prognostic factors in breast cancer patients. Oncol Rep. 1996 Sep;3(5):883-6.

73. Silva RR, Bascioni R, Rossini S, Zuccatosta L, Mattioli R, Pilone A, Delprete S, **Battelli N**, Gasparini S, Battelli T. A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer. Tumori. 1996 Jan-Feb;82(1):68-71.

74. Rupoli S, **Battelli N**, Del Prete S, Salvi A, Cinciripini A, Scortechini AR, Cantori I, Barulli S, Leoni P. [Biologic aspects and clinical use of granulocyte growth factor]. Recent Prog Med. 1995 Dec;86(12):510-7. Review. Italian.

75. Mattioli R, Silva RR, **Battelli N**, Manocchi P, Pilone A, Rossini S, Delprete S, Mazzanti P, Bascioni R, Battelli T. Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. Tumori. 1993 Dec 31;79(6):393-6. Erratum in: Tumori 1994 Aug 31;80(4):following 314.

Autorizzo il trattamento dei miei dati personali secondo la normativa privacy Reg./EU 2016/679 (GDPR) per gli scopi inerenti l'attività dichiarata.

Macerata 05.07.2022

